Edition:
United States

Catalent Inc (CTLT.N)

CTLT.N on New York Stock Exchange

42.36USD
10:52am EDT
Change (% chg)

$0.79 (+1.90%)
Prev Close
$41.57
Open
$41.95
Day's High
$42.39
Day's Low
$41.66
Volume
17,160
Avg. Vol
348,980
52-wk High
$47.86
52-wk Low
$36.74

Latest Key Developments (Source: Significant Developments)

Biohaven Says Expects Topline Results From Phase 3 Trial With Rimegepant Zydis ODT In Q4​
Tuesday, 6 Mar 2018 03:00am EST 

March 6 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN ENROLLS FIRST PATIENT IN PHASE 3 CLINICAL TRIAL TO EVALUATE RIMEGEPANT ZYDIS® ODT IN THE ACUTE TREATMENT OF MIGRAINE.BIOHAVEN - CONTINUES TO EXPECT TOPLINE RESULTS FROM TWO PHASE 3 TRIALS EXAMINING EFFICACY OF RIMEGEPANT 75 MG ORAL TABLET VERSUS PLACEBO BY END OF Q1 2018​.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD SAYS ‍EXPECTS TOPLINE RESULTS FROM PHASE 3 TRIAL WITH RIMEGEPANT ZYDIS(®) ODT IN Q4 OF 2018​.  Full Article

Matthew Walsh Appointed Chief Financial Officer Of Allergan PLC
Monday, 5 Feb 2018 07:51am EST 

Feb 5 (Reuters) - Allergan Plc ::MATTHEW M. WALSH APPOINTED EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER OF ALLERGAN PLC.ALLERGAN PLC - WALSH CURRENTLY SERVES AS EXECUTIVE VICE PRESIDENT AND CFO AT CATALENT INC.  Full Article

Catalent Posts Q2 Loss Per Share $0.16
Monday, 5 Feb 2018 07:45am EST 

Feb 5 (Reuters) - Catalent Inc ::CATALENT INC REPORTS SECOND QUARTER FISCAL 2018 RESULTS.Q2 LOSS PER SHARE $0.16.SEES FY 2018 REVENUE $2.42 BILLION TO $2.48 BILLION.Q2 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.45.WETTENY JOSEPH APPOINTED AS CHIEF FINANCIAL OFFICER.FY'18 GUIDANCE RAISED.QTRLY ‍REVENUE OF $606.3 MILLION INCREASED 25% AS-REPORTED, OR 22 PCT IN CONSTANT CURRENCY FROM PRIOR-YEAR PERIOD​.Q2 EARNINGS PER SHARE VIEW $0.33, REVENUE VIEW $567.5 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $2.41 BILLION -- THOMSON REUTERS I/B/E/S.SEES ‍2018 ADJUSTED NET INCOME IN RANGE OF $212 MILLION TO $232 MILLION​.‍EXPECTS SELF-FUNDED CAPITAL EXPENDITURES IN RANGE OF $152 MILLION TO $165 MILLION IN 2018​.WETTENY JOSEPH IS SUCCEEDING MATT WALSH, WHO ANNOUNCED DECISION TO LEAVE CO TO ASSUME POSITION OF CFO OF ALLERGAN PLC.  Full Article

Catalent Q1 earnings per share $0.03
Monday, 6 Nov 2017 07:30am EST 

Nov 6 (Reuters) - Catalent Inc ::Catalent Inc. Reports first quarter fiscal 2018 results.Q1 earnings per share $0.03.Sees FY 2018 revenue $2.31 billion to $2.41 billion.Q1 revenue $543.9 million versus I/B/E/S view $491 million.Q1 earnings per share view $0.17 -- Thomson Reuters I/B/E/S.Q1 adjusted non-gaap earnings per share $0.21.Catalent - ‍expects fiscal year 2018 adjusted EBITDA in range of $521 million to $547 million and adjusted net income in range of $198 million to $224 million​.Catalent - ‍company expects self-funded capital expenditures in range of $152 million to $165 million for FY2018 ​.Catalent - ‍expects self-funded capital expenditures in range of $152 million to $165 million for fiscal year 2018​.Fy2018 revenue view $2.31 billion -- Thomson Reuters I/B/E/S.  Full Article

Catalent announces pricing of private offering of senior unsecured notes due 2026
Monday, 16 Oct 2017 07:00am EDT 

Oct 16 (Reuters) - Catalent Inc :Catalent announces pricing of private offering of senior unsecured notes due 2026.Catalent Inc - unit ‍priced a private offering of $450.0 million in aggregate principal amount of 4.875 percent senior unsecured notes due 2026 at par​.  Full Article

Catalent launches private offering of $450 mln of senior unsecured notes due 2026
Tuesday, 10 Oct 2017 07:09am EDT 

Oct 10 (Reuters) - Catalent Inc ::Catalent announces launch of private offering of $450 million of senior unsecured notes due 2026.Catalent - intends to use net proceeds from private offering to fund, in part, purchase price of previously announced pending deal of Cook Pharmica ​.  Full Article

Catalent files for common stock offering of upto $‍​250 million
Monday, 25 Sep 2017 04:13pm EDT 

Sept 25 (Reuters) - Catalent Inc :Catalent Inc - files for common stock offering of upto $‍​250.0 million- SEC Filing.  Full Article

Catalent announces public offering of common stock to fund part of its acquisition of Cook Pharmica
Monday, 25 Sep 2017 04:12pm EDT 

Sept 25 (Reuters) - Catalent Inc :Catalent Inc announces public offering of common stock to fund part of its acquisition of Cook Pharmica.Catalent Inc - ‍has launched an underwritten public offering ( "offering") of $250.0 million of its common stock​.Catalent Inc - ‍ intends to use net proceeds of offering to fund purchase price of previously announced pending acquisition of Cook Pharmica LLC​.  Full Article

Catalent Inc to acquire Cook Pharmica for $950 million
Tuesday, 19 Sep 2017 07:30am EDT 

Sept 19 (Reuters) - Catalent Inc :Catalent to acquire Cook Pharmica for $950 million.$750 million of deal value to be paid at closing and balance to be paid in equal installments​.Acquisition is an-all cash transaction, which Catalent expects to finance with new unsecured notes and equity​.Acquisition is expected to be accretive to Catalent's adjusted net income per share in first full fiscal year following completion​.Upon completion, Cook Pharmica's over 750 associates will join Catalent's network​.Catalent has obtained committed financing for deal from Morgan Stanley Senior Funding, J.P. Morgan, RBC Capital Markets, BofA Merrill Lynch​.Purchase agreement to acquire Cook Pharmica is not subject to any financing condition​​.  Full Article

Catalent Q4 adjusted non-GAAP earnings per share $0.65
Monday, 28 Aug 2017 04:15pm EDT 

Aug 28 (Reuters) - Catalent Inc :Catalent, Inc. Reports fourth quarter and full year 2017 results.Sees FY 2018 revenue $2.16 billion to $2.24 billion.Q4 revenue $616.9 million versus I/B/E/S view $549.5 million.Q4 adjusted non-GAAP earnings per share $0.65.Q4 earnings per share $0.49.Q4 earnings per share view $0.57 -- Thomson Reuters I/B/E/S.Catalent Inc sees for fiscal year 2018 expects adjusted ebitda in range of $477 million to $497 million​.Catalent Inc - ‍ expects self-funded capital expenditures in range of $145 million to $155 million for fiscal year 2018​.Catalent Inc sees FY 2018 adjusted net income in range of $192 million to $212 million.FY2018 revenue view $2.13 billion -- Thomson Reuters I/B/E/S.FY2018 earnings per share view $1.58 -- Thomson Reuters I/B/E/S.Catalent-Fiscal year 2018 guidance ranges consistent with organic constant-currency long-term CAGR growth expectations of 4-6% for revenue,6-8% for adjusted EBITDA​.Catalent Inc - ‍ backlog for clinical supply services segment was $338.3 million as of June 30, 2017, a 3 percent increase compared to Q3 of fiscal year 2017​.  Full Article

Catalent to buy Juniper Pharmaceuticals for $11.50 per share

U.S. drug contract manufacturer Catalent Inc said on Tuesday it will buy Juniper Pharmaceuticals Inc for $11.50 per share in cash.